Partial sequence of nine <i>C</i>. <i>metapsilosis</i> clinical isolates and reference strain.

<p>(amplicon position 141 bp and 218 bp highlighted)</p

dMelt curves of reference <i>Candida</i> sp. in duplicates in <i>Candida</i> strains with two Tm values.

<p>Scale different from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0116940#pone.0116940.g001" target="_blank">Fig. 1</a>: 1) <i>C</i>. <i>pelliculosa</i>, 2) <i>C</i>. <i>tropicalis</i>, 3) <i>C</i>. <i>metapsilosis</i>, 4) <i>C</i>. <i>orthopsilosis</i>, 5) <i>C</i>. <i>parapsilosis</i>, 6) <i>C</i>. <i>lipolytica</i>, 7) <i>C</i>. <i>dubliniensis</i>, 8) <i>C</i>. <i>albicans</i>, 9) <i>C</i>. <i>catenulata</i></p

HRMA identification procedure in species with overlapping Tm ranges.

<p><b>A)</b> Tm ± 3 SD reference strains values, <b>B)</b> shapes of the selected reference strains dMelt curves, <b>C)</b> normalized and temperature–shifted difference plot of the reference strains against <i>C</i>. <i>krusei</i>. PK–positive control used in each HRMA run.</p

dMelt curves of reference <i>Candida</i> sp. in duplicates in <i>Candida</i> strains with a single Tm value.

<p>1) <i>C</i>. <i>zeylanoides</i>, 2) <i>C</i>. <i>saitoana</i>, 3) <i>C</i>. <i>utilis</i>, 4) <i>C</i>. <i>fabianii</i>, 5) <i>C</i>. <i>guilliermondii</i>, 6) <i>C</i>. <i>glabrata</i>, 7) <i>C</i>. <i>intermedia</i>, 8) <i>C</i>. <i>pulcherrima</i>, 9) <i>C</i>. <i>kefyr</i>, 10) <i>C</i>. <i>lusitaniae</i>, 11) <i>C</i>. <i>rugosa</i>, 12) <i>C</i>. <i>inconspicua</i>, 13) <i>C</i>. <i>californica</i>, 14) <i>C</i>. <i>krusei</i>, 15) <i>C</i>. <i>norvegensis</i>, 16) <i>C</i>. <i>lambica</i></p

Prevalence of atopy, asthma and allergy with regard to MBL status.

<p>–1000 ng/ml; high: >1000 ng/ml. MBL2 genotypes represent the allelic variations associated with low, intermediate or high MBL levels. Statistical analysis was performed using the Chi-square test. Serum MBL levels are regarded as low if they are <100 ng/ml; intermediate: 100</p

Clinical characteristics of the study group.

<p> AITD: autoimmune thyroid disorders. TPOAb: antibodies against thyroperoxidase. The data were obtained from questionnaires filled by the participating women.</p

MBL levels in pregnant women with and without autoimmune thyroid disorders.

<p>Overall, 103 women tested positively in a screening for AITD performed between the 9^th and 12^th gestational weeks (grouped together in the left column). They were found to be positive for TPOAb in 86 cases (of these, 12 had TSH elevation, 6 had TSH suppression; the rest was euthyroid). Of the 17 TPOAb-negative ones, 10 had TSH elevation and 7 had TSH suppression. Eighty women were negative for both parameters (right column). Horizontal bars represent median values of serum MBL.</p

Serum MBL levels in pregnant women screened for AITD.

<p>–1000 ng/ml and high: >1000 ng/ml. Low serum MBL levels: <100 ng/ml; intermediate: 100</p

Serum levels of MBL and thyroid parameters in pregnant women screened for autoimmune thyroid disorders in the 9-12^th gestational wks.

<p>^*(p<0.05), ^**(p<0.01), ^***(p<0.001) (Mann Whitney test). Positivity in screening: TSH<0.06 or >3.67 mIU/l and/or TPOAb>143 kU/l. TSH: thyroid stimulating hormone; FT4: free thyroxine; TPOAb: antibodies against thyroperoxidase. All 212 women included provided a blood sample for MBL analysis after delivery. In 103women, MBL could also be measured in a sample frozen at screening in pregnancy, which summed up to 96 pairs (pregnancy vs. follow-up). Statistical significances of comparison between values in positively vs. negatively screened women are marked by </p